Now showing items 1-5 of 5
Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics
Considering the disadvantageous of first line anti-tuberculosis (TB) drugs, including poor patient adherence, drug side effects, the long treatment duration and rapidly increasing microbe resistance, alternative treatment ...
Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis
Over the past 5 years, there has been a renewed interest in finding new compounds with anti-TB action. Colistin methanesulfonate or polymyxin E, is a possible anti-TB drug candidate, which may in future be used either alone ...
New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis
(Oxford Univ Press, 2016)
Objectives: Rifampicin is considered the most important antibiotic for treating TB, but unfortunately Mycobacterium tuberculosis is rapidly developing resistance to this drug. Despite the fervent research efforts to date, ...
TB or not TB? Improving the understanding and diagnosis of tuberculosis through metabolomics
(Future Medicine, 2016)
“ ...metabolomics has resulted in an exponential increase in the number of newly identified tuberculosis biomarkers, which has not only shed light on previously unknown disease mechanisms, but could potentially ...
A comparison of four sputum pre-extraction preparation methods for identifying and characterising Mycobacterium tuberculosis using GCxGC-TOFMS metabolomics
In many pulmonary diseases, sputum is a valuable sample material for use in disease characterisation and diagnostics. However, due to its high viscosity and uneven consistency (lumpiness), it is difficult to obtain ...